GlobalData

Phase IIa data show faster infection resolution and shorter hospital stays when AP-SA02 is added to standard antibiotic therapy,…

Three major deals contributed 79.7 per cent of the total deal value during September 2025

Regulators haven’t specified how many trials are affected, though therapies like CAR-T, which sometimes use overseas manufacturing…

The GlobalData has revealed that the global pharmaceuticals sector has witnessed a slowdown in deal-making activity in August…

While India’s pharma startups can resolve scientific and systemic blind spots, funding remains the missing link blocking scalable…

The imposition of tariffs threatens to elevate costs, creating uncertainty in launch planning, particularly for late-stage assets…

With ten other drugs in Phase III development by domestic companies, according to GlobalData’s Pharmaceutical Intelligence Center,…

Promising biomarkers may include proteins such as serum amyloid A3 (SAA3)

Seven out of the top 20 companies registered over 10 per cent YoY revenue growth from 2023 to 2024

GlobalData epidemiologists forecast the total prevalent cases of chronic hepatitis B (CHB) in the 7MM* to reach nearly 4 million…